CureVac’s Covid Vaccine Performed Badly in Trial, In Part Due to Variants

The results were a blow to hopes that the vaccine could help meet the world’s urgent need. “This is pretty devastating” for the company, one expert said.

from NYT > Top Stories https://ift.tt/3iRcv0T
via IFTTT